Who was studied, and how
Eight numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
empagliflozin
metformin
Probably raised triglyceride levels+12.9
Probably lowered diastolic blood pressure−13.4
Probably raised HDL cholesterol+6.47
randomisedthe abstract, start to end
… sitagliptin, and metformin arm (-1.8, -1.35, -0.69%).
… led to reductions in SBP about - 8.27 mm Hg (95% CI: -13.31, -3.23; P = 0.001) and in DBP about - 13.37 mm Hg (95% CI: -16.42, -10.32; …
… group relative to the metformin group (-4.1 vs. -0.90 kg; p = 0.044).
… in the empagliflozin group was - 12.91 mg/dl (95% CI: 31.82, 6; P = 0.001) for triglyceride (TG) levels and 6.47 mg/dl (95% CI: 2.93, 10.01; …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
HbA1Cempagliflozin vs baseline
−1.8
HbA1Csitagliptin vs baseline
−1.35
HbA1Cmetformin vs baseline
−0.69
Blood pressure
−8.27−13.3 to −3.23
Weightempagliflozin vs metformin
−4.1
Triglyceride (TG) levelsempagliflozin vs metformin
12.916.00–31.8
DBPempagliflozin vs metformin
−13.4−16.4 to −10.3
High-density lipoprotein (HDL-c) levelsempagliflozin vs metformin
6.472.93–10.0
MetforminSGLT2 inhibitorsDPP-4 inhibitorsGlycemic controlBody weight & compositionLipidsBlood pressure
1 / 5